A Phase III Trial Evaluating Both Erlotinib And Chemoradiation As Adjuvant Treatment For Patients With Resected Head Of Pancreas Adenocarcinoma
Posted Date: May 15, 2019
- Investigator: Kevin Redmond
- Specialties:
- Type of Study: Drug
Gemcitabine is standard treatment for patients with pancreatic cancer that was removed by surgery. In this study, participants will get either gemcitabine alone or gemcitabine combined with erlotinib. The use of erlotinib to prevent the recurrence of pancreatic cancer after surgery is investigationa
Criteria:
Eligible Patients Must Have Pancreatic Cancer That Was Removed By Surgery. Eligibility Requires Ther
Keywords:
Gastric Cancer, Gi Cancer, Pancreatic Adenocarc, Pancreatic Cancer, R0848
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu